Metastatic Hormone Refractory Prostate Cancer Recruiting Phase 2 Trials for Nivolumab (DB09035)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

IndicationStatusPhase
DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03554317COMbination of Bipolar Androgen Therapy and NivolumabTreatment